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Background: Insulin-like growth factor 1 receptor (IGF-1R) regulates cell growth, prolif-
eration, and apoptosis. Adenocarcinoma and never-smokers have a higher expression 
of IGF-1R, which is associated with worse overall survival. Dalotuzumab-MK0646 (D) is a 
humanized monoclonal antibody that targets IGF-1R. Pemetrexed (P) has higher activity 
in non-squamous lung cancer (NSQL). We initiated a randomized phase II trial to test the 
combination of P and Cisplatin (C) ± D in NSQL.
Methods: Eligibility criteria were untreated NSQL stage IV, ECOG 0 or 1, measurable dis-
ease, adequate renal, hepatic and hematologic function, and no other intercurrent illness. 
P at 500 mg/m2 and C at 75 mg/m2 IV were given every 3 weeks. D was given at 10 mg/
kg IV weekly on days 1, 8, and 15 of every 3-week cycle in the experimental group. The 
patients had a radiographic assessment after every two cycles and were treated for a 
maximum of six cycles if there was a response or stable disease. The primary objective 
of the study was to compare the clinical response rates of PC vs. PC + D.
results: From 1/2009 to 2/2011, the study accrued 26 subjects: 16 male and 10 female, 
with a median age of 59; 14 were treated with PC and 12 were treated with PC + D. 
We observed two partial responses (PR), seven stable disease (SD), three progressive 
disease (PD), and two not evaluable (NE) in the PC arm. In comparison, for the PC + D 
arm, there were three PR, four SD, four PD, and one NE. The hematologic toxicity was 
similar in both groups. There was higher incidence of hyperglycemia in the experimental 
group; four cases with grade 3 and one case with grade 4.
Conclusion: PC + D had a similar response rate compared to PC, with a higher rate 
of hyperglycemia. Identification of responders using predictive markers would be key to 
continuing the study of D in NSQL.
Trial registration: NCT00799240, clinicaltrials.gov
Keywords: dalotuzumab, non-squamous cell lung cancer, metastatic, iGF-1r, pemetrexed, treatment
FiGUrE 1 | iGF-1r system and related receptors. IR, insulin receptor; EGFR, epidermal growth factor receptor.
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inTrODUCTiOn
Insulin-like growth factor 1 receptor (IGF-1R) is a tyrosine kinase 
receptor that regulates cell growth, proliferation, and apoptosis 
(1) (Figure  1). Increased IGF1 signaling results in increased 
proliferation and inhibition of apoptosis through RAF and PI3K 
pathways (2). Several types of cancer, including non-small cell 
lung cancer, express IGF-1R and its ligand. The serum levels of 
IGF are regulated by IGF-binding protein (IGFBP), which causes 
sequestration of IGF. Increased expression of IGFBP-3 is associ-
ated with improved outcome in resected stage I lung cancer (3). 
High expression of IGF-1R is associated with poor survival in 
surgically resected stage I adenocarcinoma which along with 
never-smokers had a higher expression of IGF-1R compared to 
squamous histology or smokers (4). Low IGF-1R expression was 
associated with significant improvement in survival in adenocar-
cinoma, while there was no correlation between IGF-1R expres-
sion and survival in patients with squamous histology. The use of 
an IGF-1R inhibitor is a potential new strategy in the treatment 
of lung cancer.
Figitumumab (F) was the first humanized monoclonal anti-
body targeting the IGF-1R studied in lung cancer. Initial phase II 
study showed promising results, especially in the squamous lung 
cancer histology (5). This agent was later studied in a large phase 
III trial but terminated early due to increased toxicity (6).
Dalotuzumab (D) or MK-0646 is a humanized monoclonal 
antibody specific to IGF-1R and does not bind insulin receptor 
(IR). It is an IgG1 isotype with potential to elicit an antibody-
dependent cellular cytotoxicity (ADCC) response. The analysis 
of safety parameters of phase I studies demonstrated that D has 
been associated with thrombocytopenia, leukocytoclastic vascu-
litis, and hyperglycemia with no infusion reactions. Based on the 
phase I trial data, 10 mg/kg weekly is the recommended phase II 
dose. We proposed a randomized phase II trial to study the use of 
D in non-squamous lung cancer (NSQL) comparing pemetrexed 
(P)/cisplatin (C) vs. PC + D as first line therapy. We hypothesized 
that D could be synergistic with chemotherapy P + C in NSQL.
The study opened in January 2009 and it closed in February 
2011 due to a decision from one of the sponsoring companies. We 
present data the 26 subjects enrolled in this study.
FiGUrE 2 | Study schema.
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MaTErialS anD METHODS
The study was conducted under IND number 103120 and was 
reviewed and approved by the Institutional Review Board at 
the University of Kansas and Veteran’s Administration Medical 
Center Kansas City participating sites. The study was registered 
in the clinicaltrials.gov identifier NCT00799240.
The study included subjects 18 years or older who were able 
to give informed consent for treatment and laboratory explora-
tory studies. Patients needed an ECOG performance status of 
0–1 with histologically or a cytological-proven newly diagnosed 
Stage IV (by AJCC seventh edition) advanced primary non-small 
cell bronchogenic lung cancer (non-squamous cell, including 
bronchoalveolar, adenocarcinoma, large cell carcinoma, or 
unspecified). If pleural effusion was clinically significant, thora-
centesis was performed prior to initiation of therapy. Patients with 
symptomatic brain metastases were eligible after brain radiation 
and were neurologically stable, as well as off dexamethasone for 
at least 1 week prior to registration. Patients with asymptomatic 
brain metastasis were eligible if they did not require radiation and 
were neurologically stable without dexamethasone.
Measurable disease was documented by CT, MRI, X-ray, or 
physical exam, and assessed within 28 days before registration. 
Previous radiation or surgery was permitted if it was completed 
1 and 4 weeks prior to registration. Patient must have recovered 
from all associated toxicities at the time of registration. Measurable 
disease must be present outside the area of surgical resection or 
radiation field; adequate bone marrow function which is defined 
by platelet count ≥100,000/mm3, hemoglobin ≥9  g/dl, leuko-
cyte count ≥3,000/mm3, or absolute neutrophil count ≥1,500/
mm3 and adequate hepatic function defined by bilirubin ≤1.5× 
upper normal limit, AST or ALT, and alkaline phosphatase all 
≤3× institutional upper limit of normal (IULN) were required 
within 28 days prior to registration (except in presence of known 
hepatic metastasis, wherein AST or ALT may be up to 5× upper 
normal limit). Serum creatinine must be ≤ IULN with calculated 
or measured creatinine clearance must be ≥50 ml/mm using the 
Crockroft Gault formula. Women with childbearing potential 
required a negative serum pregnancy test; NSAIDS were to be 
discontinued 2  days before (5  days for long-acting NSAIDs), 
the day of, and 2 days following administration of P; folic acid, 
vitamin B12, and dexamethasone were administered according 
to protocol.
Subjects were excluded if they had prior systemic chemo-
therapy or biologic therapy for non-small cell lung cancer. If 
neoadjuvant or adjuvant therapy were given, they must be at least 
1 year out from the last chemotherapy dose and fully recovered 
from all toxicities. Additional exclusion criteria were uncon-
trolled congestive heart failure, high blood pressure, unstable 
angina, or myocardial infarction within the prior year, serious 
cardiac arrhythmias requiring medication, serious uncontrolled 
active infection, acute hepatitis or known HIV, uncontrolled 
diabetes mellitus defined as a hemoglobin A1C ≥7. Patients 
with a prior history of severe allergy (grade 3 or 4) to human 
monoclonal antibody, concurrent use of human growth hormone 
or growth hormone inhibitors, and prior active malignancy in the 
past 2 years were also excluded. Persons of reproductive potential 
must have agreed to use two methods of effective contraception 
prior to, during, and for 4 weeks after study therapy.
STaTiSTiCal COnSiDEraTiOnS
The primary objective of the study was to compare the objective 
response rate between the two arms using RECIST criteria version 
1. We estimated a target improvement from 30% in the control 
arm A using PC to 45% in the experimental arm B using PC + D. 
The secondary objective was to determine the progression-free 
survival (PFS) and overall survival (OS), the toxicity profile using 
CTC version 3, and exploratory laboratory analysis of IGF expres-
sion in the serum and tumor. PFS was defined as the duration 
of time from start of treatment to time of progression or death, 
whichever came first. Survival was determined from randomiza-
tion to time of death due any cause. Kaplan–Meier curves and log 
rank tests were used to compare arms.
This was a randomized phase II study (Figure  2) designed 
to estimate the response rate based on multiple constraints. We 
wanted to estimate the response rate in each arm with a SE of no 
>10% as well as to estimate the margin of error for the difference 
in the response rates within 20%, with a 90% confidence interval. 
Three different scenarios were considered optimal, one-to-one 
randomization, and two-to-one randomization (experimental to 
control). Based on the expected response rates of 30% in standard 
of care and 45% in the experimental group, the one-to-one design 
was chosen. Thus, a total of 31 evaluable patients in each arm 
were required for this study. We planned to randomize a total of 
68 subjects to allow for a 10% non-evaluable rate. Subjects were 
randomized upon entry into the study.
TrEaTMEnT
Arm A group received P at 500  mg/m2 IV every 21  days with 
C 75 mg/m2 IV every 21 days for six cycles with P infused first, 
followed by C. Arm B received PC with the same dose schedule as 
TaBlE 1 | Patient characteristics.
Number of patients N = 26
Gender 10 Female:16 male
Median age 59 (range 41–83)
Disease sites Malignant effusion (4) distant metastases (22)
Treatment Pemetrexed/cisplatin (PC)
N = 14
Dalotuzumab with PC
N = 12
ECOG performance 
status
0 (4) 1 (10) 0 (4) 1 (8)
Median age 61 58
Gender 8 Male:6 female 8 Male:4 female
Stage IV Malignant pleural effusion (3) Malignant effusion (1)
Distant disease (11) Distant disease (11)
Sites of disease Bone (7) Bone (5)
Brain (3) Brain (4)
Adrenal (4) Adrenal (3)
Liver (3) Contralateral lung (3)
Extra-thoracic node (2) Extra-thoracic node (2)
Chest wall (1) Malignant pleural effusion (1)
Malignant pleural effusion (4)
No. of cycles 6 Cycles (6) 6 Cycles (7)
5 Cycles (1) 5 Cycles (1)
4 Cycles (2) 2 Cycles (3)
3 Cycles (1) 1 Cycle (1)
2 Cycles (2)
1 Cycle (1)
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above with D at 10 mg/kg IV on days 1, 8, and 15 for every 21 days 
with PC infused first followed by D.
We gave premedication with vitamin supplementation consist-
ing of folic acid 350–1,000 μg orally daily starting 1 week before P 
and continued during therapy; B12 1,000 μg IM starting 1 week 
before P then every 9  weeks during therapy and continuing 
until 3 weeks after completion of chemotherapy in both groups. 
Dexamethasone was given 4 mg bid/day the day before, the day 
of treatment, and the day after P. Patients also received standard 
pre- and post-hydration and antiemetic at the discretion of treat-
ing physician prior to C chemotherapy.
Arm B received additional premedication with benadryl 
50 mg IV, acetaminophen 650 mg orally, and ranitidine 50 mg 
IV. As precaution, patients were observed for up to 1 h after the 
end of infusion of D. The observation area was supplied with 
resuscitation equipment and other agents (epinephrine, pred-
nisone equivalents, etc.). Vital signs (blood pressure, heart rate, 
respiratory rate, and temperature) were checked prior to, midway, 
at the completion of D, and 1 h after D. The study utilized the NCI 
Common Terminology Criteria for Adverse Events (CTCAE) 
Version 3.0 for toxicity and Serious AE reporting. Dose modifica-
tions were performed according to pre-established toxicity crite-
ria. Once a dose was reduced, it remained so for all subsequent 
cycles. If multiple toxicities occurred, dose modifications were 
based on the toxicity requiring the largest dose reduction.
We performed an interim toxicity analysis after six patients 
were enrolled in Arm B (PC + D), which was pre-specified in the 
protocol. There were no observed excessive grade 3 or 4 toxicities 
and the study continued to enroll additional subjects.
Patients were removed from protocol treatment if they had 
progression of disease as defined by RECIST 3.0; symptomatic 
deterioration; unacceptable toxicity, chemotherapy treatment 
delay for >3  weeks from the scheduled treatment date for any 
reason; D treatment delay >4  weeks from the scheduled treat-
ment date for any reason except hyperglycemia; or by patient 
choice. After completion of active therapy, patients were followed 
every 8  weeks for 18  months after registration or until disease 
progression or death (whichever came first).
rESUlTS
The study accrued 26 subjects, and it was stopped due a spon-
sor’s decision. We had 19 patients that did not enter in the trial 
due screen failure due a variety of reasons (7 patients declined 
to participate, 2 had recent surgery and did not recover, 1 due 
to physician decision, 1 had EGFR mutation positive and went 
to have treatment with EGFR TKI, 1 hospitalized due disease, 1 
had insurance disapproval to participate in clinical trial, 1 due 
study termination) with 5 not meeting study criteria (2 had per-
formance status >1, 1 due to creatinine clearance bellow 50 ml/
min, 1 had squamous histology on pathology review, and 1 did 
not have stage IV on PET scan).
There were 10 females and 16 males, with a median age of 
59 years old (range 41–83). Four had malignant pleural effusion 
and 22 had distant metastatic disease. We accrued 14 in arm A 
(PC) and 12 in arm B (PC +  D). Dose reduction occurred in 
three patients in arm A: two patients that had dose reduction of C 
(given at 37 mg/m2) due to renal dysfunction and one patient had 
dose reduction of P (given at 375 mg/m2) and C. Dose reduction 
also occurred in three patients in arm B: two patients that had 
dose reduction of C due renal dysfunction and one patient had 
dose reduction of C and Dalotuzumab (given at 6 mg/kg) at cycle 
6 day 15 due hearing toxicity. The number of cycles given in arm 
A was six cycles (6); five cycles (1); four cycles (2); three cycles 
(1); two cycles (2); and one cycle (1). Reason for discontinuation 
before six cycles were six due to progression of disease, one due 
renal failure and decrease in performance status, and one patient 
was lost to follow-up. The number of cycles given in arm B was 
six cycles (7); five cycles (1); two cycles (3); and one cycle (1). 
Reason for discontinuation before six cycles was four patients due 
progression of disease and one due renal failure (Table 1). The 
AE events are listed in Table 2. The hematologic toxicities were 
comparable between both groups. As would be predicted from an 
IGF-1R inhibitor, there was a higher incidence of hyperglyecemia 
(three grade 3 and one grade 4) in arm B vs. none in arm A. There 
was one toxicity-related death in arm A after complications of 
chemotherapy due to sepsis.
Arm A (PC) had two partial responses (PR) (14%), one stable 
disease (SD) and three disease progression with two patients not 
evaluable (NE) (one due to complications from chemotherapy 
and one lost to follow-up). The median time to progression was 
173 days and the median survival was 262 days. Arm B (PC + D) 
had three patients with PR (25%), four SD, four disease progres-
sion, and one NE. The median time to progression was 199 days 
and median survival was 276.5  days (Table  3). The figures for 
time to progression, OS, and an example of the response obtained, 
are depicted in Figures 3 and 4, respectively. Incomplete accrual 
limited statistical analysis.
TaBlE 3 | results.
arm a arm B
Pemetrexed/cisplatin Dalotuzumab with pemetrexed/cisplatin
PR 2 PR 3
SD 7 SD 4
PD 3 PD 4
NE 2 NE 1
Median time to progression Median time to progression
173 days 199 days
Median survival Median survival
262 days 276.5 days
PR, partial response; SD, stable disease; PD, progression of disease; NE, not 
evaluable.
TaBlE 2 | Toxicities related to therapy.
Pemetrexed/cisplatin arm a Dalotuzumab with pemetrexed/cisplatin arm B
Hematologic non-hematologic Hematologic non-hematologic
Grade 1 Platelet (1); INR (1); leukocyte (1); 
hemoglobin (1)
5 Most common: nausea (13); hypokalemia 
(7); constipation (6); creatinine (6); fever (3)
Hemoglobin (7); leukocyte (6); 
neutrophil (5)
5 Most common: nausea (7); diarrhea 
(5); fatigue (5); hyperglycemia (5); 
anorexia (4)
Grade 2 Hemoglobin (4); leukocyte (4); 
neutrophil (2); platelet (2)
Fatigue (5); tinnitus (4); diarrhea (4); vomiting 
(4); nausea (4)
Leukocyte (6); lymphopenia (4); 
neutrophil (3); hemoglobin (2)
Fatigue (7); hyperglycemia (5); tinnitus 
(3); dehydration (2); hypotension (2)
Grade 3 Febrile neutropenia (2); 
leukopenia (1); hemoglobin (1); 
neutrophil (1); platelet (2)
1 Each: hyponatremia; dysphagia; urinary 
tract infection; fatigue; hypoalbuminemia, 
metabolic laboratory; esophageal stenosis; 
hypoxia, muscle weakness; dyspnea (2)
Hemoglobin (3); neutrophils (3); 
lymphopenia (1)
Hyperglycemia (4); 1 each: hearing; 
pain extremity; muscle weakness; 
hypokalemia; nausea
Grade 4 Hemoglobin (1); platelet (2) Hypoxia (1); sepsis (1) Hyperglycemia (1)
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DiSCUSSiOn
The first clinical experience using an IGF-1R monoclonal anti-
body was with F. Preclinical studies showed that it has activity 
as a single agent and it was synergistic when combined with 
chemotherapy (7, 8). A phase I study in 24 patients showed no 
toxicities greater than grade 3 with clinical activity, 3 SD, and 
7 minor tumor reduction (9). A phase II study combining F 
with paclitaxel/carboplatin (TCb + F) as first line treatment of 
advanced non-small lung cancer had 2:1 randomization with 
73 patients. It compared TCb +  F for six cycles followed by 
maintenance with F vs. TCb alone with potential for crossover if 
progression on or no response with TCb alone. The study showed 
a response rate of 46% in the TCb + F arm vs. 32% in the TCb 
arm. Subgroup analysis showed a 71% response in patients with 
squamous cell histology. There was evidence of single-agent 
activity in one patient who progressed on TCb, then crossed over 
to F alone with stabilization of disease (5). Hyperglycemia (12%) 
and dehydration (58%) all grades were the most common side 
effects. A subsequent phase III trial using TCb with or without F 
in non-small cell lung cancer was suspended by the Data Safety 
Monitoring Board in September 2009 due to increased grade 5 
toxicity in the TCb + F arm (6). Grade 5 AE occurred in 13% 
of patients in the TCb +  F compared with 10% in TCb arm. 
Treatment-related grade 5 AE occurred in 5% of TCb + F and 
1% in the TCb arm. The response rate, median PFS, and median 
OS for the TCb + F arm and TCb arm were similar, 33 vs. 35%; 
4.7 vs. 4.6 m, and 8.6 vs. 9.8 m, respectively. Subsequent interim 
analysis showed that addition of F with TCb would not to meet 
the primary endpoint of improving OS compared with TCb. Since 
the presentation of this phase III trial in the ASCO 2010 annual 
meeting, several companies halted the development of this class 
of agent in lung cancer. The publication of the phase II trial with 
F was later retracted by the authors in October 2012 (10). The 
reason for retraction was due to non-adherence to the RECIST 
recommendation for follow-up CT scan to confirm responses 
discovered during routine study close-out review. The revised 
response rate was 37.4% in the TCb + F arm and 27.5% in the 
TCb arm. The response in the squamous histology was 43.8%. 
The median PFS was 4.3 m, 4.4 m for F at 10 mg/kg, and 4.5 m at 
20 mg/kg, p = 0.816.
In our study with a limited number of patients treated with 
D, we observed similar response rates, PFS, and OS in the group 
receiving PC + D and PC. There was difference in the toxicity 
regarding hyperglycemia in patients treated with D most likely 
due to class effect. These results are not definitive since the study 
did not complete accrual to allow proper statistical analysis. We 
did not observe a higher grade 5 toxicity in the experimental 
arm, implying that there may be a difference of these antibod-
ies, chemotherapy used, or lack of maintenance therapy with D. 
Unfortunately, we cannot clarify these questions since IGF-1R 
class of drug is no longer in the development of lung cancer.
If we were to resurrect the study of this agent, future research 
should be guided by a biomarker to help in patient selection. 
Serum levels of free IGF-1 might be such a biomarker. The phase 
III trial using F showed that patients with lower levels of baseline 
IGF-1(<120  ng/ml) had increased incidence of grade 5 AE vs. 
higher levels of IGF-1, 56% and 35%, respectively, with HR of 
1.37 in patients with low baseline IGF-1 treated with TCb + F. The 
median OS was better in patients with higher levels of IGF-1 com-
pared with lower levels of IGF-1 treated with TCb and F, 10.4 and 
7 m, respectively. A similar effect of IGF-1 levels and outcomes 
were demonstrated in a study by Hixon et al. The median PFS 
was longer in patients with high free IGF-1 when they received 
TCb + F (20 mg/kg) vs. TCb, 6.53 and 2.73 months, respectively 
(p = 0.001) (11). Altogether, this information indicate that high 
IGF-1 level may help us select the population that will benefit 
from IGF-1R-based therapy with lower toxicity. Exactly how the 
high levels of IGF-1 result in lower toxicity is not clear.
Another area of research should be in mechanism of resistance 
and in formulation of strategies to overcome this resistance. The 
FiGUrE 4 | Overall survival.
FiGUrE 3 | Time to progression.
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IGF-1R pathway activates both the PI3K/AKT/mTOR and RAS 
pathways in parallel (12). Furthermore, the homolog IR (13) as 
well as the cMET (14) and EGFR (15) pathways could also be 
involved in the resistance by simultaneous over-activation, in 
order to evade the blockade of IGF-1R. Mutation in these receptors 
and downstream protein during the course of therapy could lead 
to resistance to IGF-1R-targeted agents and render them ineffec-
tive. The complexity of these pathways is tremendous and further 
research using genomic/exome sequencing could determine the 
predominant mechanism of resistance, and assist us in the selec-
tion of agents to be used in combination with IGF-1R-targeted 
agent in order to circumvent resistance and characterize the 
patient population that will benefit from this therapy.
COnClUSiOn
This report is the first clinical report using D in non-squamous 
cell lung cancer in combination with PC. The study showed 
similar response rate, PFS, and OS in both groups; however, 
this results lack statistical significance since the study did not 
complete accrual. We did not observe significant increased 
hematologic or grade 5 toxicity in this limited group of patients 
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treated with PC + D. We observed increased frequency of grade 3 
hyperglycemia associated with D which is a class effect. The use of 
IGF-1R-targeted therapy is no longer under investigation in lung 
cancer. It is possible that patients with high IGF-1 levels could 
benefit from IGF-1R directed agents with lower toxicity. Future 
research should be directed toward defining response biomarker, 
mechanism of resistance, and patient selection that would benefit 
from IGF-1R pathway inhibition.
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